Top-Rated StocksTop-RatedNASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free RGEN Stock Alerts $158.20 -0.16 (-0.10%) (As of 09:45 AM ET) Add Compare Share Share Today's Range$158.20▼$162.2150-Day Range$157.06▼$199.7452-Week Range$110.45▼$211.13Volume19,189 shsAverage Volume532,302 shsMarket Capitalization$8.83 billionP/E Ratio219.73Dividend YieldN/APrice Target$196.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Repligen alerts: Email Address Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside24.2% Upside$196.70 Price TargetShort InterestBearish8.85% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment-0.30Based on 10 Articles This WeekInsider TradingSelling Shares$5.04 M Sold Last QuarterProj. Earnings Growth43.15%From $1.46 to $2.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.84 out of 5 starsMedical Sector94th out of 924 stocksBiological Products, Except Diagnostic Industry12th out of 150 stocks 2.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRepligen has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.85% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Repligen has recently decreased by 3.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 1.5 News and Social Media Coverage News SentimentRepligen has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Repligen this week, compared to 5 articles on an average week.Search Interest2 people have searched for RGEN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 5 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,039,532.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 43.15% in the coming year, from $1.46 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 219.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 133.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 219.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 162.78.Price to Earnings Growth RatioRepligen has a PEG Ratio of 5.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesMay 2, 2024 | gurufocus.comQ1 2024 Repligen Corp Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst ProjectionsMay 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…May 1, 2024 | investorplace.comRGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | msn.comRepligen reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | globenewswire.comRepligen Reports First Quarter 2024 Financial ResultsApril 29, 2024 | nasdaq.comRGEN Quantitative Stock AnalysisApril 25, 2024 | americanbankingnews.comRepligen (NASDAQ:RGEN) Shares Gap Up to $157.48May 2, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 24, 2024 | americanbankingnews.comRepligen (RGEN) to Release Earnings on WednesdayApril 23, 2024 | finance.yahoo.comShould be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?April 19, 2024 | markets.businessinsider.comPositive Report for Repligen (RGEN) from Craig-HallumApril 18, 2024 | nasdaq.comRepligen Corporation Common Stock (RGEN)April 17, 2024 | finance.yahoo.comRepligen to Report First Quarter 2024 Financial ResultsApril 17, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - RGENApril 12, 2024 | finance.yahoo.comArtisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share AppreciationApril 9, 2024 | markets.businessinsider.comRBC Capital Remains a Buy on Repligen (RGEN)March 19, 2024 | globenewswire.comRepligen Appoints Maggie A. Pax to Board of DirectorsMarch 18, 2024 | finance.yahoo.comAre Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?March 16, 2024 | finance.yahoo.comRGEN Apr 2024 150.000 callMarch 12, 2024 | finance.yahoo.comRepligen Corp CEO Anthony Hunt Sells 16,707 SharesFebruary 28, 2024 | morningstar.comRepligen Corp RGENFebruary 27, 2024 | finance.yahoo.comRepligen Corp COO James Bylund Sells 4,373 SharesFebruary 26, 2024 | finance.yahoo.comEstimating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)February 24, 2024 | msn.comRepligen (RGEN) Price Target Increased by 8.15% to 203.98February 24, 2024 | finance.yahoo.comDecoding Repligen Corp (RGEN): A Strategic SWOT InsightFebruary 22, 2024 | benzinga.comRepligen Stock (NASDAQ:RGEN), Short Interest ReportSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$196.70 High Stock Price Target$220.00 Low Stock Price Target$165.00 Potential Upside/Downside+24.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.72 Trailing P/E Ratio219.95 Forward P/E Ratio108.47 P/E Growth5.38Net Income$41.58 million Net Margins6.51% Pretax Margin10.04% Return on Equity5.00% Return on Assets3.78% Debt Debt-to-Equity Ratio0.26 Current Ratio7.02 Quick Ratio5.75 Sales & Book Value Annual Sales$638.76 million Price / Sales13.84 Cash Flow$2.92 per share Price / Cash Flow54.27 Book Value$35.31 per share Price / Book4.48Miscellaneous Outstanding Shares55,840,000Free Float55,169,000Market Cap$8.84 billion OptionableOptionable Beta1.03 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 60)CEO & Director Comp: $885kMr. Olivier Loeillot (Age 54)President & Chief Commercial Officer Comp: $1.49MMr. Jason K. Garland (Age 50)CFO & Chief Compliance Officer Comp: $282.99kMr. James R. Bylund (Age 60)Chief Operating Officer Comp: $472.18kMs. Christine Gebski (Age 56)Senior Vice President of Filtration & Chromatography Comp: $396.09kMr. Ralf Kuriyel (Age 66)Senior Vice President of Research & Development Comp: $401.74kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral Counsel & Global Head of LegalDr. Jaime M. Humara Ph.D.Senior Vice President of Global MarketingMore ExecutivesKey CompetitorsAcceleron PharmaNASDAQ:XLRNExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALONeurocrine BiosciencesNASDAQ:NBIXDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 66,864 shares on 5/1/2024Ownership: 0.144%Capstone Investment Advisors LLCSold 12,358,169 shares on 5/1/2024Ownership: 0.003%Diversify Advisory Services LLCBought 1,766 shares on 5/1/2024Ownership: 0.003%Connecticut Wealth Management LLCBought 1,091 shares on 5/1/2024Ownership: 0.002%Retirement Systems of AlabamaBought 172 shares on 4/30/2024Ownership: 0.117%View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Repligen stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price target for 2024? 9 brokerages have issued twelve-month target prices for Repligen's shares. Their RGEN share price targets range from $165.00 to $220.00. On average, they anticipate the company's stock price to reach $196.70 in the next year. This suggests a possible upside of 24.2% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2024? Repligen's stock was trading at $179.80 on January 1st, 2024. Since then, RGEN stock has decreased by 11.9% and is now trading at $158.36. View the best growth stocks for 2024 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts' consensus estimates of $0.33. The biotechnology company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a trailing twelve-month return on equity of 5.00% and a net margin of 6.51%. The firm's quarterly revenue was down 16.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.68 EPS. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), Congress SMid Growth ETF (CSMD), VanEck Biotech ETF (BBH) and Nuveen ESG Mid-Cap Growth ETF (NUMG). What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). Who are Repligen's major shareholders? Repligen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (2.03%), Conestoga Capital Advisors LLC (1.34%), Riverbridge Partners LLC (0.80%), Principal Financial Group Inc. (0.62%), Allspring Global Investments Holdings LLC (0.60%) and Allspring Global Investments Holdings LLC (0.60%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More This page (NASDAQ:RGEN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
